Takeda completes 75 million-euro Russian pharmaceutical production plant

11 September 2012

Takeda Pharmaceutical International GmbH said this morning that it has completed the construction at its pharmaceutical manufacturing facility in Yaroslavl, Russia, adding to the list of pharma majors, including Novartis and AstraZeneca, which have been prompted by Russia’s Pharma 2020 program regulations, designed to support local production.

The company, a subsidiary of Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502), has invested around 75 million euros ($94.8 million) in the 24,000m2 production plant, which is expected to be fully operational by 2014. Foreign pharma manufacturing investment in Russia has been projected to reach some $1.4 billion (The Pharma Letter March 24, 20110). The Russian investment was announced in 2009 by Nycomed, the Swiss company that Takeda acquired, largely to capitalize on its strong showing in emerging markets.

Expects to see sales increase 15% a year to 2016

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK